Interaction of herbal constituents with cytochrome P450 enzymes

Alternative and Complementary Therapies

Volumn 13, Issue 5, 2007, Pages 239-247

  Yarnell, Eric ^a,b   Abascal, Kathy ^a  

^a Botanical Medicine Academy   (United States)

^b BASTYR UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLBENZENE; ARTEMISIA ANNUA EXTRACT; ARTEMISININ; BERBERINE; CIMICIFUGA RACEMOSA EXTRACT; COMFREY EXTRACT; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; ELEUTHEROCOCCUS EXTRACT; ESTRADIOL; GINKGO BILOBA EXTRACT; HERBACEOUS AGENT; HYPERICUM PERFORATUM EXTRACT; ISOTHIOCYANIC ACID DERIVATIVE; PICEATANNOL; PIPERINE; PLANT TOXIN; PYRROLIZIDINE ALKALOID; SAFROLE; SILYBUM MARIANUM EXTRACT; SULFORAPHANE; TURMERIC; VALERIAN;

ANISE; BETEL NUT; BLACK PEPPER; CARCINOGENESIS; CRUCIFERA; DRUG METABOLISM; ENZYME ACTIVATION; ENZYME INHIBITION; ESTROGEN METABOLISM; FENNEL; GARLIC; GRAPEFRUIT JUICE; HERB DRUG INTERACTION; HUMAN; HYDRASTIS; REVIEW; SASSAFRAS; TEA; WATERCRESS;

EID: 35948958234     PISSN: 10762809     EISSN: None     Source Type: Journal    
DOI: 10.1089/act.2007.13508     Document Type: Review

References (64)

1. Bertz R, Granneman G. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997;32:210-258.
2. Whitten DL, Myers SP, Hawrelak JA, Wohlmuth H. The effect of St. John's wort extracts on CYP3A: A systematic review of prospective clinical trials. Br J Clin Pharmacol 2006;62:512-526.
3. Mai I, Bauer S, Perloff E, et al. Hyperforin content determines the magnitude of the St John's wort-cyclosporin drug interaction. Clin Pharmacol Ther 2004;76:330-340.
4. Arold G, Donath F, Maurer A, et al. No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's wort extract. Planta Med 2005;71:331-337.
5. Mathijssen RH, Verweij J, de Bruijn P, et al. Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst 2002;94:1247-1249.
6. Schwarz UI, Hanso H, Oertel R, et al. Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol. Clin Pharmacol Ther 2007;81:669-678.
7. Mertens-Talcott SU, Zadezensky I, De Castro WV, et al. Grapefruit-drug interactions: Can interactions with drugs be avoided? J Clin Pharmacol 2006;46:1390-1416.
8. Lown KS, Bailey DG, Fontana RJ, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997;99:2545-2553.
9. Kane GC, Lipsky JJ. Drug-grapefruit juice interactions. Mayo Clin Proc 2000;75:933-942.
10. Culm-Merdek KE, von Moltke LL, Gan L, et al. Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: Comparison with ritonavir. Clin Pharmacol Ther 2006;79:243-254.
11. Charbit B, Becquemont L, Lepere B, et al. Pharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine. Clin Pharmacol Ther 2002;72:514-523.
12. Kupferschmidt HH, Fattinger KE, Ha HR, et al. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol 1998;45:355-359.
13. Kawaguchi A, Ohmori M, Tsuruoka S, et al. Drug interaction between St John's wort and quazepam. Br J Clin Pharmacol 2004;58:403-410.
14. Soldner A, Christians U, Susanto M, et al. Grapefruit juice activates P-glycoprotein-mediated drug transport. Pharm Res 1999;16:478-485.
15. Dresser GK, Kim RB, Bailey DG. Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: Possible role of organic anion transporting polypeptides. Clin Pharmacol Ther 2005;77:170-177.
16. Brunner LJ, Pai KS, Munar MY, et al. Effect of grapefruit juice on cyclosporin A pharmacokinetics in pediatric renal transplant patients. Pediatr Transplant 2000;4:313-321.
17. Fuhr U. Drug interactions with grapefruit juice: Extent, probable mechanism and clinical relevance. Drug Saf 1998;18:251-272.
18. Pisarik P. Blood pressure-lowering effect of adding grapefruit juice to nifedipine and terazosin in a patient with severe renovascular hypertension. Arch Fam Med 1996;5:413-416.
19. Bailey DG, Bend JR, Arnold JM, et al. Erythromycin-felodipine interaction: Magnitude, mechanism, and comparison with grapefruit juice. Clin Pharmacol Ther 1996;60:25-33.
20. Runkel M, Tegtmeier M, Legrum W. Metabolic and analytical interactions of grapefruit juice and 1,2-benzopyrone (coumarin) in man. Eur J Clin Pharmacol 1996;50:225-230.
21. Merkel U, Sigusch H, Hoffman A. Grapefruit juice inhibits 7-hydroxylation of coumarin in healthy volunteers. Eur J Clin Pharmacol 1994;46:175-177.
22. Hukkanen J, Jacob P 3rd, Benowitz NL. Effect of grapefruit juice on cytochrome P450 2A6 and nicotine renal clearance. Clin Pharmacol Ther 2006;80:522-530.
23. Liddell JR. Pyrrolizidine alkaloids. Nat Prod Rep 2001;18:441-447.
24. Fu PP, Xia Q, Lin G, Chou MW. Pyrrolizidine alkaloids - genotoxicity, metabolism enzymes, metabolic activation, and mechanisms. Drug Metab Rev 2004;36:1-55.
25. Wang YP, Yan J, Fu PP, Chou MW. Human liver microsomal reduction of pyrrolizidine alkaloid N-oxides to form the corresponding carcinogenic parent alkaloid. Toxicol Lett 2005;155:411-420.
26. Anderson PC, McLean AEM. Comfrey and liver damage. Human Toxicol 1989;8:68-69.
27. Jeurissen SM, Bogaards JJ, Awad HM, et al. Human cytochrome p450 enzyme specificity for bioactivation of safrole to the proximate carcinogen 1′-hydroxysafrole. Chem Res Toxicol 2004;17:1245-1250.
28. Jeurissen SM, Punt A, Boersma MG, et al. Human cytochrome P450 enzyme specificity for the bioactivation of estragole and related alkenylbenzenes. Chem Res Toxicol 2007;20:798-806.
29. Lee JM, Liu TY, Wu DC, et al. Safrole-DNA adducts in tissues from esophageal cancer patients: Clues to areca-related esophageal carcinogenesis. Mutat Res 2005;565:121-128.
30. Bhardwaj RK, Glaeser H, Becquemont L, et al. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 2002;302:645-650.
31. Pattanaik S, Hota D, Prabhakar S, et al. Effect of piperine on the steady-state pharmacokinetics of phenytoin in patients with epilepsy. Phytother Res 2006;20:683-686.
32. Bano G, Raina RK, Zutshi U, et al. Effect of piperine on bioavailability and pharmacokinetics of propranolol and theophylline in healthy volunteers. Eur J Clin Pharmacol 1991;41:615-617.
33. Johri RK, Zutshi U. An Ayurvedic formulation "Trikatu" and its constituents. J Ethnopharmacol 1992;37:85-91.
34. Durgaprasad S, Pai CG, Vasanthkumar, et al. A pilot study of the antioxidant effect of curcumin in tropical pancreatitis. Indian J Med Res 2005;122:315-318.
35. Appiah-Opong R, Commandeur JN, van Vugt-Lussenburg B, Vermeulen NP. Inhibition of human recombinant cytochrome P450s by curcumin and curcumin decomposition products. Toxicology 2007;235:83-91.
36. Juan H, Terhaag B, Cong Z, et al. Unexpected effect of concomitantly administered curcumin on the pharmacokinetics of talinolol in healthy Chinese volunteers. Eur J Clin Pharmacol 2007;63:663-668.
37. Nakajima M, Yoshida R, Shimada N, et al. Inhibition and inactivation of human cytochrome P450 isoforms by phenethyl isothiocyanate. Drug Metab Dispos 2001;29:1110-1113.
38. Petri N, Tannergren C, Holst B, et al. Absorption/metabolism of sulforaphane and quercetin, and regulation of phase II enzymes, in human jejunum in vivo. Drug Metab Dispos 2003;31:805-813.
39. Higdon JV, Delage B, Williams DE, Dashwood RH. Cruciferous vegetables and human cancer risk: Epidemiologic evidence and mechanistic basis. Pharmacol Res 2007;55:224-236.
40. Fowke JH. Head and neck cancer: A case for inhibition by isothiocyanates and indoles from cruciferous vegetables. Eur J Cancer Prev 2007;16:348-356.
41. Juge N, Mithen RF, Traka M. Molecular basis for chemoprevention by sulforaphane: A comprehensive review. Cell Mol Life Sci 2007;64:1105-1127.
42. Hamilton SM, Teel RW. Effects of isothiocyanates on cytochrome P-450 1A1 and 1A2 activity and on the mutagenicity of heterocyclic amines. Anticancer Res 1996;16:3597-3602.
43. Felton JS, Knize MG, Bennett LM, et al. Impact of environmental exposures on the mutagenicity/carcinogenicity of heterocyclic amines. Toxicology 2004;198:135-145.
44. Probst-Hensch NM, Tannenbaum SR, Chan KK, et al. Absence of the glutathione S-transferase M1 gene increases cytochrome P4501A2 activity among frequent consumers of cruciferous vegetables in a Caucasian population. Cancer Epidemiol Biomarkers Prev 1998;7:635-638.
45. Leclercq I, Desager JP, Horsmans Y. Inhibition of chlorzoxazone metabolism, a clinical probe for CYP2E1, by a single ingestion of watercress. Clin Pharmacol Ther 1998;64:144-149.
46. Chen L, Mohr SN, Yang CS. Decrease of plasma and urinary oxidative metabolites of acetaminophen after consumption of watercress by human volunteers. Clin Pharmacol Ther 1996;60:651-660.
47. Fishman J, Osboren MP, Telang NT. The role of estrogen in mammary carcinogenesis. Ann NY Acad Sci 1995:768:91-100.
48. Lord RS, Bongiovanni B, Bralley JA. Estrogen metabolism and the diet-cancer connection: Rationale for assessing the ratio of urinary hydroxylated estrogen metabolites. Altern Med Rev 2002;7:112-129.
49. Bell MC, Crowley-Nowick P, Bradlow HL, et al. Placebo-controlled trial of indole-3-carbinol in the treatment of CIN. Gynecol Oncol 2000;78:123-129.
50. Naik R, Nixon S, Lopes A, et al. A randomized phase II trial of indole-3-carbinol in the treatment of vulvar intraepithelial neoplasia. Int J Gynecol Cancer 2006;16:786-790.
51. Rosen CA, Bryson PC. Indole-3-carbinol for recurrent respiratory papillomatosis: Long-term results. J Voice 2004;18:248-253.
52. Wong GY, Bradlow L, Sepkovic D, et al. Dose-ranging study of indole-3-carbinol for breast cancer prevention. J Cell Biochem 1997;Suppl 28-29:111-116.
53. Bapiro TE, Sayi J, Hasler JA, et al. Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans. Eur J Clin Pharmacol 2005;61:755-761.
54. Svensson US, Ashton M. Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin. Br J Clin Pharmacol 1999;48:528-535.
55. Ashton M, Hai TN, Sy ND, et al. Artemisinin pharmacokinetics is time-dependent during repeated oral administration in healthy male adults. Drug Metab Dispos 1998;26:25-27.
56. Ashton M, Sy ND, Huong NV, et al. Artemisinin kinetics and dynamics during oral and rectal treatment of uncomplicated malaria. Clin Pharmacol Ther 1998;63:482-493.
57. Gordi T, Xie R, Jusko WJ. Semi-mechanistic pharmacokinetic/ pharmacodynamic modelling of the antimalarial effect of artemisinin. Br J Clin Pharmacol 2005;60:594-604.
58. Rath K, Taxis K, Walz G, et al. Pharmacokinetic study of artemisinin after oral intake of a traditional preparation of Artemisia annua L (annual wormwood). Am J Trop Med Hyg 2004;70:128-132.
59. Potter GA, Patterson LH, Wanogho E, et al. The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br J Cancer 2002;86:774-778.
60. Piver B, Fer M, Vitrac X, et al. Involvement of cytochrome P450 1A2 in the biotransformation of trans-resveratrol in human liver microsomes. Biochem Pharmacol 2004;68:773-782.
61. Ovesná Z, Kozics K, Bader Y, et al. Antioxidant activity of resveratrol, piceatannol and 3,3′,4,4′,5,5′-hexahydroxy- trans-stilbene in three leukemia cell lines. Oncol Rep 2006;16:617-624.
62. Bobrowska-Hägerstrand M, Lillas M, Mrówczyñska L, et al. Resveratrol oligomers are potent MRP1 transport inhibitors. Anticancer Res 2006;26:2081-2084.
63. Yin OQ, Tomlinson B, Waye MM, et al. Pharmacogenetics and herb-drug interactions: Experience with Ginkgo biloba and omeprazole. Pharmacogenetics 2004;14:841-850.
64. Svensson US, Ashton M, Trinh NH, et al. Artemisinin induces omeprazole metabolism in human beings. Clin Pharmacol Ther 1998;64:160-167.